Citation Impact
Citing Papers
Clinical importance of acquired cystic disease of the kidney in patients undergoing dialysis.
1983 StandoutNobel
Do general practitioners miss dementia in elderly patients?
1988
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Do Prognostic Parameters of Remission versus Relapse after Bacillus Calmette–Guérin (BCG) Immunotherapy Exist? Analysis of a Quarter Century of Literature
2003
d-Galactose-induced accelerated aging model: an overview
2019 Standout
Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement
2008
Testicular Germ-Cell Cancer
1997 Standout
Guidelines on Urolithiasis<footref rid="foot01"><sup>1</sup></footref>
2001 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
2016
Clinical experience with holmium:YAG laser lithotripsy of ureteral calculi
1996
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
1996
Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia
1997
Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
2003 Standout
Clock-drawing: is it the ideal cognitive screening test?
2000 Standout
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Acute Renal Failure
1996 Standout
Posterolateral Endoscopic Excision for Lumbar Disc Herniation
2002 Standout
Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review
2005
A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C
2007
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer
1998
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
2005
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Rapid MR Imaging Detection of Renal Cysts: Age-based Standards
2001
Venous thromboembolism (VTE) in Europe
2007 Standout
Photodynamic therapy and anti-tumour immunity
2006 Standout
Alternating Mitomycin C and BCG Instillations versus BCG Alone in Treatment of Carcinoma in Situ of the Urinary Bladder: A Nordic Study
2003
Prevention of Venous Thromboembolism
2004 Standout
Holmium:YAG Laser Ureterolithotripsy
1999
Cancer immunotherapy comes of age
2011 StandoutNature
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Prevention of Venous Thromboembolism
2008 Standout
The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003
Comparison of Two Diets for the Prevention of Recurrent Stones in Idiopathic Hypercalciuria
2002 Standout
The aging kidney
2008
A meta‐analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia
2004
Microwave thermotherapy for benign prostatic hyperplasia
2007
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
Points of control in inflammation
2002 StandoutNature
Treatment of Persistent Gross Hematuria with Tranexamic Acid in Autosomal Dominant Polycystic Kidney Disease
2017 Standout
Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment
1998
Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy.
1995
Molecular Fingerprinting ofMycobacterium tuberculosis: How Can It Help the Clinician?
1997
A Case of Pott’s Disease with Epidural Abscess and Probable Cerebral Tuberculoma following Bacillus Calmette‐Guérin Therapy for Superficial Bladder Cancer
2010
Intravesical Therapy of Bladder Cancer: An lmmunotherapy Success Story
1996
Motor recovery after stroke: a systematic review
2009 Standout
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
2010
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Hospital-acquired renal insufficiency
2002 Standout
Renal Function in Aging
1989
Principles and Applications of Laser Lithotripsy: Experience with the Holmium Laser Lithotrite
1998
Interaction Between Photodynamic Therapy and BCG Immunotherapy Responsible for the Reduced Recurrence of Treated Mouse Tumors¶
2001
Acquired cystic disease of kidney in chronic dialysis patients
1981
Fatal Sepsis Following Intravesical Bacillus Calmette-Guerin Administration for Bladder Cancer
1990
Double-Blind Study with Thiazide in Recurrent Calcium Lithiasis
1982
Intravesical Versus Intravesical Plus Intradermal Bacillus Calmette-Guerin: A Prospective Randomized Study In Patient With Recurrent Superficial Bladder Tumors
1996
Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.
1996 StandoutNobel
A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?
1991
The elderly patient with acute renal failure.
1995
THE AGEING KIDNEY
1978
Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients
2006
Bladder Cancer
2020 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
2000 Standout
2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa
2015 Standout
MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY
2000 Standout
Nephron obstruction in nordihydroguaiaretic acid-induced renal cystic disease
1979
Arthroscopic Microdiscectomy and Selective Fragmentectomy
1998
Evolution and Clinical Significance of the T Cell Proliferative and Cytokine Response Directed Against the Fibronectin Binding Antigen 85 Complex of Bacillus Calmette-Guerin During Intravesical Treatment of Superficial Bladder Cancer
1997
Hereditary polycystic kidney disease (adult form): A microdissection study of two cases at an early stage of the disease
1978
Original Articles: Bladder Cancer: Intravesical Adjuvant Chemotherapy for Superficial Transitional Cell Bladder Carcinoma: Results of 2 European Organization for Research and Treatment of Cancer Randomized Trials With Mitomycin C and Doxorubicin Comparing Early Versus Delayed Instillations and Short-Term Versus Long-Term Treatment
1995
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events
2008
The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter Study
2006
Microwave thermotherapy for benign prostatic hyperplasia
2012
Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
1997
Intracorporeal Lithotripsy With the Holmium:YAG Laser
1996
Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes
2012 Standout
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
2002 Standout
Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery
2001
Works of A Steg being referenced
Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph.
1996
Immunohistochemical Markers Defined by Monoclonal Antibodies and Response to Bacillus Calmette-Guérin Endovesical Immunotherapy for Superficial Bladder Tumors
1990
Systemic Bacillus Calmette-Guérin Infection, ‘BCGitis’, in PatientsTreated by Intravesical Bacillus Calmette-Guérin Therapy forBladder Cancer
1989
Genitourinary Tumors and HIVi Infection
1990
Complete Ureteral Transection Associated with Percutaneous Lumbar Disk Nucleotomy
1992
Clinical Experience with a new Pulsed Dye Laser for Ureteral Stone Lithotripsy
1990
Intravesical BCG therapy in patients with superficial bladder tumors.
1989
Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer
1992
Decrease in Mortality from Benign Prostatic Hyperplasia: a Major Unheralded Health Triumph
1996
Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.
1989
Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.
1989
Hyperthermia: a randomized prospective study applying hyperthermia or a sham procedure in obstructive benign hyperplasia of the prostate.
1994
On the pathogenesis of simple renal cysts in the adult
1977
Effects of Pulsed Dye Laser Lithotripsy on Tissues
1988
Is the Diverticulum of the Distal and Collecting Tubules a Preliminary Stage of the Simple Cyst in the Adult?
1977
[Recent data on the urinary excretion of oxalic acid in oxalic renal lithiasis].
1972
Localized Hyperthermia Versus the Sham Procedure in Obstructive Benign Hyperplasia of the Prostate: A Prospective Randomized Study
1992
SUBCUTANEOUS ENOXAPARINE (LOVENOXR) VERSUS PLACEBO FOR PREVENTING DEEP VEIN THROMBOSIS (DVT) AFTER TRANSURETHRAL PROSTATECTOMY (TUP)
1987
Cystic changes in adult human kidneys after ureteral obstruction Microdissection studies
1976
Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications.
1989
Cyproterone Acetate Lead-In Prevents Initial Rise of SerumTestosterone Induced by Luteinizing Hormone-Releasing HormoneAnalogs in the Treatment of Metastatic Carcinoma of the Prostate
1986